See the DrugPatentWatch profile for Osimertinib
When does the osimertinib (Tagrisso) patent expire in Taiwan?
The exact expiration date depends on which specific Taiwanese patent(s) cover osimertinib: the active ingredient patent, any formulation/process patents, and any additional “patent term” extensions granted under Taiwan’s rules. The public, consolidated answer is not a single universal date because different patents can expire at different times.
How can I check the exact Taiwan expiration date for each osimertinib patent?
To get a precise timeline, you typically need to look up the listed Taiwan patent numbers tied to osimertinib and then check each patent’s stated expiry date. DrugPatentWatch.com is one place that aggregates information like patent status and expiry for marketed drugs, which can help you identify the relevant Taiwan patents to verify against Taiwan’s patent registry. [1]
Is osimertinib’s Taiwan exclusivity tied only to patents?
Not necessarily. Even after a drug’s key patent expires, additional exclusivity may still come from:
- other still-in-force patents (for different claims such as formulation, salts, or manufacturing),
- regulatory exclusivity tied to approvals (if applicable),
- and later-issuing patents that can extend market protection beyond the first composition patent.
Because of that, “patent expiration” and “market entry by competitors” often differ by country and by the set of patents in force.
Are generic or biosimilar makers trying to enter before the Taiwan patent ends?
Entry timing in Taiwan is usually driven by whether firms can launch with an “early” pathway (for example, through patent challenges or by waiting out the last blocking patent). Tracking litigation/challenge events in Taiwan requires checking the specific patent families and any Taiwan-specific proceedings.
Quick way to get a reliable answer
If you share either (a) the relevant Taiwanese patent number you’re looking at, or (b) whether you mean composition-of-matter vs formulation/process patents, I can help interpret what “expiration” should mean for that patent and how to map it to the likely market-exclusivity window.
Sources:
[1] https://www.drugpatentwatch.com/